Skip to main content
    P

    Progyny Inc (PGNY)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NASDAQ

    $36.18
    -0.40 (-1.09%)

    Market Cap: $2.66B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Progyny Inc (PGNY) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Progyny (PGNY) to earn $2.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.38B. Of 12 analysts, 10 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.

    RatingAnalystsShare
    Strong Buy18.3%
    Buy975.0%
    Hold216.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 13.7% and revenue estimates rise 11.6%.

    Fiscal year ending Dec 31, 2026
    $2.11
    EPS consensus, revenue $1.38B
    Fiscal year ending Dec 31, 2027
    $2.40
    EPS consensus, revenue $1.54B
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.11$2.10 to $2.138$1.38B$1.37B to $1.38B10
    Dec 31, 2027$2.40$2.31 to $2.578$1.54B$1.52B to $1.57B10

    Quarterly Estimates

    The EPS consensus rises from $0.35 for the quarter ending Dec 31, 2026 to $0.57 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.35$0.30 to $0.4014$362.33M$334.18M to $380.92M13
    Mar 31, 2027$0.57$0.55 to $0.615$366.82M$360.77M to $375.30M6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 7 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202650
    Quarter ending Mar 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.4% from $2.08.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$2.11$2.08$2.08$2.08$2.08+1.4%
    Fiscal year ending Dec 31, 2027$2.40$2.31$2.32$2.32$2.30+4.4%
    Quarter ending Mar 31, 2027$0.57$0.55$0.55$0.55$0.55+4.8%

    Frequently Asked Questions About PGNY

    What is the PGNY stock forecast?

    Consensus analyst estimates put Progyny's EPS at $2.11 for the fiscal year ending Dec 31, 2026, on revenue of $1.38B. The consensus rating from 12 analysts is Buy.

    How do analysts rate PGNY stock?

    Of 12 analysts covering Progyny, 1 rates it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PGNY next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.11, with estimates from $2.10 to $2.13 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.40, with estimates from $2.31 to $2.57 from 8 analysts.

    What revenue do analysts expect from Progyny next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.38B, with estimates from $1.37B to $1.38B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.54B, with estimates from $1.52B to $1.57B.

    How many analysts cover PGNY?

    12 analysts rate Progyny stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.